医学
肝细胞癌
肝硬化
丙型肝炎病毒
肝病
丙型肝炎
病毒
免疫学
病毒学
内科学
作者
Marianne Martinello,Sunil S. Solomon,Norah A. Terrault,Gregory J. Dore
出处
期刊:The Lancet
[Elsevier]
日期:2023-09-01
卷期号:402 (10407): 1085-1096
被引量:49
标识
DOI:10.1016/s0140-6736(23)01320-x
摘要
Hepatitis C virus (HCV) is a hepatotropic RNA virus that can cause acute and chronic hepatitis, with progressive liver damage resulting in cirrhosis, decompensated liver disease, and hepatocellular carcinoma. In 2016, WHO called for the elimination of HCV infection as a public health threat by 2030. Despite some progress, an estimated 57 million people were living with HCV infection in 2020, and 300 000 HCV-related deaths occur per year. The development of direct-acting antiviral therapy has revolutionised clinical care and generated impetus for elimination, but simplified and broadened HCV screening, enhanced linkage to care, and higher coverage of treatment and primary prevention strategies are urgently required.
科研通智能强力驱动
Strongly Powered by AbleSci AI